Table 3.
Patient subgroup according to established and potential biomarkers of targeted therapies in gastric cancer
| Biomarker* | Established/in clinical trials‡ | N | Specifications |
|---|---|---|---|
| ERBB2 amplification | First line: trastuzumab+chemotherapy Third line: trastuzumab, deruxtecan NCT05190445, NCT05152147, NCT02465060, NCT04143711 |
4 (4/81, 4.9%) | Assay A: 1/49, 2.0% Assay B: 3/32, 9.4% |
| FGFR2 amplification | NCT05019794, NCT04189445 | 5 (5/81, 6.2%) | Assay A: 1/49, 2.0% Assay B: 4/32, 12.5% |
| FGFR1 amplification | NCT05019794, NCT04189445 | 1 (1/81, 1.2%) | Assay A: 0/49, 0.0% Assay B: 1/32, 3.1% |
| EGFR amplification | NCT04077255, NCT04739202 | 3 (3/81, 3.7%) | Assay A: 2/49, 4.1% Assay B: 1/32, 3.1% |
| CCNE1 amplification† | NCT05252416 | 3 (3/32, 9.4%) | - |
| RAS mutation or amplification† | NCT02465060 | 12 (9/81, 11.1%; 3/32, 9.4%) | Assay A: 5/49, 10.2% Assay B: 4/32, 12.5% 9 mutations (8 KRAS, 1 NRAS) 3 KRAS amplifications |
| TP53 mutation | NCT03641313 | 31 (31/81, 38.3%) | Assay A: 17/49, 34.7% Assay B: 14/32, 43.8% 35 mutations in 31 patients |
| PIK3CA mutation or amplification† | NCT04526470, NCT04739202, NCT02465060 | 2 (2/81, 2.5%) | Assay A: 1/49, 2.0% Assay B: 1/32, 3.1% 2 mutations No amplification |
| ARID1A mutation† | NCT05379972 | 3 (3/32, 9.4%) | 4 mutations from 3 patients |
| MET amplification | NCT04923932, NCT05620628, NCT05439993, NCT03993873, NCT02465060 | 3 (3/81, 3.7%) | Assay A: 3/49, 6.1% Assay B: 0/32, 0.0% |
| TSC2 null† | NCT02465060 | 1 (1/32, 3.1%) | p.Phe471LeufsTer14 from #69 patient |
†CCNE1 amplification, KRAS amplification, PIK3CA amplification, ARID1A mutation, and TSC2 null were only evaluated in the 32 patients tested using assay B (AlphaLiquid 100 kit).
‡Phase II or III clinical trials with “active, not recruiting” or “recruiting” status are listed.
Abbreviation: NCT, national clinical trial.